ADDICTION TREATMENT STARTS HERE: PRIMARY CARE (ATSH:PC)
DATES, MEASURES AND DEFINITIONS

Data Submission Due Dates	Quarter	Dates for Pulling Data
April 15, 2019	Q1	January 1 – March 31, 2019
July 15, 2019	Q2	April 1 – June 30, 2019
October 15, 2019	Q3	July 1 – September 30, 2019
January 15, 2020	Q4	October 1 – December 31, 2019
April 15, 2020	Q5	January 1 – March 31, 2020
July 15, 2020	Q6	April 1 – June 30, 2020

FOR MORE INFORMATION, VISIT:

https://www.careinnovations.org/atshprimarycare-teams/data-reporting/

Required – Access Measures		
	MEASURE	DEFINITION
A.	Adoption	
A1	# of x-waivered prescribers	Total number of physicians, nurse practitioners or physician assistants, onsite and with whom the health center has contracts, who have obtained a Drug Addiction Treatment Act of 2000 (DATA) waiver to treat opioid use disorder with medications approved by the U.S. FDA for this indication. This number must be current up to the reporting date. Planned, in process or pending waivers do not count.
A2	# of x-waivered prescribers actively prescribing	Total number of prescribers who have prescribed buprenorphine for opioid use disorder (OUD) to at least 1 patient over the three months prior to or on the reporting date.
A3	% of x-waivered prescribers of all eligible prescribers in practice	The numerator is calculated by the # in A1. The denominator is calculated by the total # of physicians, certified nurse practitioners and physician assistants who work onsite and who are under contract at the ATSH participating health center location. This denominator does not include providers at other locations of the participating health center.
A4	Ratio of x-waivered prescribers actively prescribing to the clinic's total patient panel size	The numerator is calculated by the # in A2. The denominator is calculated by an estimate of the total number of patients at, or active panel size of, the ATSH participating health center location.
B.	Reach	
B1	# of patients prescribed buprenorphine	The total number of unique patients in the ATSH participating health center location with a current, active prescription for buprenorphine. The buprenorphine medication should be FDA approved for the indication of OUD. Included patients may be newly prescribed or established. "Active" is defined as a prescription covering any of the past 30 days of the reporting month. This number must be current up to the reporting date.
B2	# of patients prescribed naltrexone long acting injection	The total number of patients in the ATSH participating health center location with a current, active prescription for naltrexone long acting injection. Included patients may be newly prescribed or established. "Active" is defined as a prescription covering any of the past 30 days of the reporting month. This number must be current up to the reporting date.
B3	% of patients prescribed buprenorphine or naltrexone long acting injection of all patients with OUD	The numerator is calculated by adding the total number of patients in B1 + B2. The denominator is calculated by counting the number of patients in the ATSH participating health center location with a current ICD10 or DSM5 diagnosis of OUD (i.e. valid within the past 30 days). This percentage is to be calculated quarterly during the ATSH project.

Required – Access Measures (continued)		
	MEASURE	DEFINITION
C.	Retention	
C1	# of patients prescribed buprenorphine or naltrexone long acting injection 6 months prior who have adhered to this medication continuously for 6 consecutive months	Total number of patients started on either buprenorphine or naltrexone long acting injection at 6 months prior to the reporting date, and who have remained in care continuously and without interruption. This includes new patients who have started on medication and continued with refills, and who have attended clinic visits. This also includes established patients who may have discontinued treatment for at least 2 months and have been "restarted".
C2	% of patients prescribed buprenorphine or naltrexone long acting injection 6 months ago who have continued in treatment for 6 consecutive months of all patients prescribed buprenorphine or naltrexone long acting injection 6 month prior	The numerator is calculated in C1. The denominator is calculated by including a count of the total of all patients started on either buprenorphine or naltrexone long acting injection at 6 months prior to the reporting date. This percentage is to be calculated only on the data panel of eligible patients (i.e. those who started or restarted at 6 months prior to the reporting date) at every quarter of the ATSH project.

Optional – Quality Measures		
	MEASURE	DEFINITION
D.	Screening	
D1	% of patients screened for opioid use disorder of all patients seen during the last quarter	The numerator is calculated by counting the number of patients screened over the past 3 months. A standardized measure for OUD risk must be used to count in the numerator. Some options for measures include: NIDA Quick Screen, Drug Abuse Screening Test (DAST), DSM5 Checklist, the Tobacco, Alcohol, Prescription Medication and Other Substance Use (TAPS1 or TAPS 2), PRIME 1.1.1 or other validated screening tools. The denominator is calculated by counting the number of all patients seen during the last 3 months. The goal is at least 1 screening for OUD risk per year for all patients. This percentage is to be calculated quarterly during the ATSH project, and only for those patients not included in the previous quarter period data calculation.
E.	Initiation	
E1	% of patients with 1 follow-up visit within 14 days of starting buprenorphine or naltrexone long acting injection	The numerator is calculated by counting the number of patients started on either buprenorphine or naltrexone long acting injection and making at least 1 follow-up visit to the clinic within 14 days (2 weeks) of their initial prescription. Either individual or group visits count in the numerator. The denominator is calculated by counting the total number of patients prescribed either buprenorphine or naltrexone long acting injection. This percentage is to be calculated quarterly during the ATSH project, and only for those patients not included in the previous quarter period data calculation.
F.	Engagement	
F1	% of patients with 2 follow-up visits within 30 days of the date of the initial prescription for buprenorphine or naltrexone long acting injection	The numerator is calculated by counting the number of patients prescribed either buprenorphine or naltrexone long acting injection and making at least 2 follow-up visits (either individual or group) to the clinic within 30 days of their initial prescription. The denominator is calculated by counting the total number of patients prescribed either buprenorphine or naltrexone long acting injection. This percentage is to be calculated quarterly during the ATSH project, and only for those patients not included in the previous quarter period data calculation.

Optional – Quality Measures (continued)		
	MEASURE	DEFINITION
G.	Toxicology Monitoring	
G1	% of patients prescribed buprenorphine or naltrexone long acting injection who received a urine toxicology test within 3 days of starting of all patients starting their medication	The numerator is calculated by counting the number of patients prescribed either buprenorphine or naltrexone long acting injection with documentation of one or more urine toxicology test results within 3 days of starting either medication. If a saliva toxicology or other validated toxicology test is performed and documented, this counts towards the numerator. The denominator is calculated by counting the total number of patients prescribed either buprenorphine or naltrexone long acting injection. This percentage is to be calculated quarterly during the ATSH project, and only for those patients not included in the previous quarter period data calculation.
G2	% of patients taking buprenorphine or naltrexone long acting injection receiving a urine toxicology test at least once per month of all patients taking buprenorphine or naltrexone long acting injection	The numerator is calculated by pulling toxicology documentation on patients in C1 and counting the number who have at least 6 urine toxicology tests. The denominator is all patients in C1. This percentage is to be calculated quarterly during the ATSH project, and only for those patients not included in the previous quarter period data calculation.